> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Dr. Reddy’s, XenoPort Agreement on Psoriasis Therapy
- URL: https://www.fdaweb.com/dr-reddys-xenoport-agreement-on-psoriasis-therapy/
- Published: 2016-03-28T12:00:00.000Z
- Updated: 2026-09-14T20:51:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135206

> Dr. Reddy’s Laboratories and XenoPort have entered into a license agreement that grants Dr. Reddy’s exclusive U.S. rights for developing and commercializing XenoPort’s clinical-stage oral new chemical entity XP23829 for treating moderate-to-severe chronic plaque psoriasis. The therapy is also being considered for treating patients with relapsing forms of multiple sclerosis.  
>  
> Under the terms of the agreement, XenoPort will receive a $47.5 million up-front payment and an additional $2.5 million for transfer of certain clinical trial materials to Dr. Reddy’s. XenoPort will also be eligible to receive up to $190 million if certain regulatory milestones are met and up to $250 million upon the achievement of certain commercial milestones.  
>  
> XP23829 is considered a novel fumaric acid ester, according to the companies. Fumaric acid esters possess a “unique anti-inflammatory mechanism of action and have been used to treat psoriasis in Germany for over 20 years,” they say.